Analisi di costo-efficacia dello switch da un antipsicotico orale a risperidone a rilascio prolungato nel trattamento dei pazienti affetti da schizofrenia
- 36 Downloads
Parole chiaveantipsicotico costo-efficacia risperidone RP schizofrenia switch
The aim of this study was to assess the cost-effectiveness of treatment with long-acting injectable risperidone compared with previous oral antipsychotic regimens in patients with schizophrenia. The analysis was conducted from the Health Service of Regione Lombardia perspective.
An observational, two-years long, retrospective study was conducted in 28 schizophrenic patients who were undergoing a treatment switch from oral antipsychotics to risperidone RP. The effectiveness of long-acting injectable risperidone compared with previous oral antipsychotics, defined as the absence of relapses (hospitalizations), was assessed at 12 months of treatment. The study considered direct medical costs referred to year 2007 values.
In terms of effectiveness, at 12 months after switching to long-acting injectable risperidone, there was a higher percentage of patients who did not require hospitalization (67.9%) as compared retrospectively with the same period for the previous treatments (28.6%).
Long-acting risperidone showed the best expected cost versus other oral antipsychotic treatments (€9, 191.45 vs €10, 125.57). The difference in favour of risperidone (€934.12) was mainly due to lower costs for hospitalization.
On the basis of these findings, which were obtained in real-world clinical practice, long-acting injectable risperidone is predicted to be the dominant strategy because it results in effective symptom control and direct medical cost savings.
Unable to display preview. Download preview PDF.
- 3.Garattini L, Rossi C, Tediosi F, et al. Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani. PharmacoEconomics-Italian Research Articles 2002; 4: 81–89Google Scholar
- 4.Mapelli V, Bezzi R, Erlicher A, et al. Costi ed efficacia della cura della schizofrenia con antipsicotici tipici e atipici PharmacoEconomics-Italian Research Articles 2004; 6: 15–30Google Scholar
- 5.Ravasio R, Ferrannini L. Costo-efficacia di risperidone iniettabile a rilascio prolungato nel trattamento della schizofrenia in Italia. Un’analisi di confronto versus risperidone orale, olanzapina orale e aloperidolo decanoato. PharmacoEconomics-Italian Research Articles 2006; 8: 19–31Google Scholar
- 7.Tansella M, de Girolamo G. La diffusione dei disturbi mentali nella comunità. In: Cassano GB, Dell’Acqua G, Garattini S, et al. (editors). La salute mentale. Contro il pregiudizio il coraggio delle cure. Roma: Il Pensiero Scientifico Editore, 2001: 7–12Google Scholar
- 11.CCOHTA. Pharmacoeconomic evaluations of clozapine in treatment resistant schizophrenia and risperidone in chronic schizophrenia. Technology overview: pharmaceuticals 1997; 7: 1–15Google Scholar
- 15.Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 27: 213–18Google Scholar
- 16.Dellva MA, Tran P, Tollefson GD, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance of schizophrenia. Psychiatr Serv 1998; 49: 699Google Scholar
- 17.www.nice.org.uk/guidance/index.jsp?action=download&o=42140. Data ultimo accesso marzo 2009
- 23.Duncan JC, Rogers R. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci 1998; 46: 1133–7Google Scholar
- 30.Marder SR Overview of partial compliance. J Clin Psychiatry 2003; 64: 3–9Google Scholar
- 35.Chue P, Llorca PM, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005; 5: 266–74Google Scholar
- 36.Olivares JM, Rodriguez-Martinez A, Burón JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia. A 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008; 6: 41–53PubMedCrossRefGoogle Scholar